RichardBNotoMD

Nuclear Medicine • East Providence, RI

Physician

Join to view full profile

Dr. Noto is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Noto's full profile

Already have an account?

Office
20 Catamore Blvd
East Providence, RI 02914
Phone+1 401-432-2520

Fax+1 401-432-2457

Education & Training

University of Pennsylvania Health SystemResidency, Nuclear Medicine, 1986 - 1988
NYU Grossman School of MedicineResidency, Radiology-Diagnostic, 1983 - 1986
Zucker School of Medicine at Hofstra/NorthwellInternship, Internal Medicine, 1982 - 1983
University of Rochester School of Medicine and DentistryClass of 1982

Certifications & Licensure

MA State Medical License 2000 - 2025
RI State Medical License 1988 - 2024
NY State Medical License 1983 - 2002
PA State Medical License 1986 - 1988
American Board of Nuclear Medicine Nuclear Medicine
American Board of Radiology Diagnostic Radiology

Clinical Trials

A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma Start of enrollment: 2009 Jun 04
Active, not recruiting
Phase 2

Publications & Presentations

PubMed

171 citations
Efficacy and Safety of High-Specific-Activity 131I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma
Daniel A. Pryma, Bennett B. Chin, Richard B. Noto, Joseph S. Dillon, Stephanie M. Perkins
Journal of Nuclear Medicine. 2019-05-01
40 citations
Isolated sentinel lymph node dissection with conservative management in patients with squamous cell carcinoma of the vulva: A prospective trial
Richard G. Moore, Katina Robison, A.K. Brown, Paul DiSilvestro, Margaret M. Steinhoff
Gynecologic Oncology. 2008-04-01
39 citations
Phase 1 Study of High-Specific-Activity I-131 MIBG for Metastatic and/or Recurrent Pheochromocytoma or Paraganglioma.
Richard B. Noto, Daniel A. Pryma, Jessica Jensen, Tess Lin, Nancy Stambler
The Journal of Clinical Endocrinology and Metabolism. 2018-01-01

Lectures

Long-term survival and safety from a multi-center, open-label, pivotal phase 2 study of iobenguane I 131 in patients (Pts) with unresectable, locally advanced or metas...
2019 ASCO Annual Meeting - 6/1/2019